
CLAIMS

1. A pharmaceutical composition, comprising the following components in weight portions:

(a) 1 part of the compound of formula (I)



(I); and

(b) 15 to 45 parts of copovidone with a glass transition temperature of 90℃ to 130℃,

wherein components (a) and (b) are mixed and undergo hot melt extrusion.

2. The pharmaceutical composition of claim 1, wherein components (a) and (b) are mixed and undergo hot melt extrusion at a temperature in the range of 80 ℃-135℃.

3. The pharmaceutical composition of claim 1, comprising 20 to 40 parts of copovidone.

4. The pharmaceutical composition of claim 1, comprising 22 to 33 parts of copovidone.

5. The pharmaceutical composition of claim 1, further comprising:

(c) 0.1 to 3.0 parts of one or more pharmaceutically acceptable excipients selected from the group consisting of non-volatile weak acids, neutral or weakly acidic inorganic substances, and pharmaceutically acceptable excipients with melting point lower than 80℃, wherein components (a), (b) and (c) are mixed and undergo hot melt extrusion at a temperature in the range of 80℃-135℃.

6. The pharmaceutical composition of claim 5, wherein the one or more

pharmaceutically acceptable excipients comprise anhydrous citric acid, citric acid monohydrate, or a mixture thereof.

7. The pharmaceutical composition of claim 5, wherein the one or more pharmaceutically acceptable excipients comprise one or more neutral or weakly acidic inorganic substances selected from the group consisting of mannitol, lactose monohydrate, lactose anhydrous, sorbitol, calcium hydrogen phosphate anhydrous and colloidal silicon dioxide.

8. The pharmaceutical composition of claim 5, wherein the one or more pharmaceutically acceptable excipients comprise one or more excipients selected from one or more of the group c polyethylene glycol, polyethylene glycol 4000, polyethylene glycol 6000; lipidic materials, triethyl citrate, vitamin E, polyethylene glycol succinate; antioxidants, 2,6-di-tert-butyl-p-cresol, surfactants, Poloxamer 188 and Tween 80.

9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated in a tablet or capsule form.

10. A method for preparing the pharmaceutical composition of claim 1, comprising the steps of:

extruding a mixture of components (a) and (b) by hot melt extrusion at hot melt extrusion temperature is between 80℃ and 135℃ to form an extrusion product;

cooling the extrusion product; and

breaking the cooled extrusion product into granules, particles or powders by cutting, crushing or grinding.

11. The method of claim 10, further comprising the step of:

processing the granules, particles or powders obtained in the breaking step into tablets, capsules.

12. The method of claim 10, wherein the mixture of components (a) and (b)


is extruded with a twin screw hot melt extrusion device; wherein the screw diameter of the twin screw hot melt extrusion is between 8 mm and 50 mm, and the extrusion speed is between 10 rpm and 300 rpm, wherein retention time of the hot melt extrusion is less than 30 min.

13. A method of treating steatohepatitis, comprising the steps of:

administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 1.

14. A pharmaceutical composition, comprising the following components in weight portions:

(a) 1 part of the compound shown in Formula (I);



(I); and

(b) 6 to 20 parts of hydroxypropyl methylcellulose with a glass transition temperature of 90℃ to 130℃,

wherein components (a) and (b) are mixed and undergo hot melt extrusion.

15. The pharmaceutical composition of claim 14, wherein components (a) and (b) are mixed and undergo hot melt extrusion at a temperature in the range of 80℃-135℃.

16. The pharmaceutical composition of claim 14, further comprising:

(c) 0.1 to 3.0 parts of one or more pharmaceutically acceptable excipients selected from the group consisting of non-volatile weak acids, neutral or weakly acidic inorganic substances, and pharmaceutically acceptable excipients with melting point lower than 80℃, wherein components (a), (b) and (c) are mixed and undergo hot melt extrusion at a temperature in the range of 80℃-135℃.

17. The pharmaceutical composition of claim 16, comprising 0.2 to 2.0 parts of one or more pharmaceutically acceptable excipients.

18. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition is formulated in a tablet or capsule form.

19. A method for preparing the pharmaceutical composition of claim 14, comprising the steps of:

extruding a mixture of components (a) and (b) by hot melt extrusion at hot melt extrusion temperature is between 80℃ and 135℃ to form an extrusion product;

cooling the extrusion product; and

breaking the cooled extrusion product into granules, particles or powders by cutting, crushing or grinding.

20. A method of treating steatohepatitis, comprising the steps of:

administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 14.